Challenges in the evaluation of safety and efficacy of human tissue and cell based products

ANZ Journal of Surgery

Volumn 76, Issue 9, 2006, Pages 843-849

  Zheng, Ming H ^a   Pembrey, Richard ^b   Niutta, Silvana ^b   Stewart Richardson, Patricia ^b   Farrugia, Albert ^b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b THERAPEUTIC GOODS ADMINISTRATION   (Australia)

Author keywords

Cell product; Efficacy; Human tissue; Safety

Indexed keywords

CELL EXTRACT; HUMAN TISSUE AND CELL BASED PRODUCT; TISSUE EXTRACT; UNCLASSIFIED DRUG;

ALTERNATIVE MEDICINE; CADAVER; CYTOMEGALOVIRUS; DISEASE TRANSMISSION; DRUG EFFICACY; DRUG SCREENING; EOSINOPHILIA MYALGIA SYNDROME; EPSTEIN BARR VIRUS; ETHICS; EVALUATION; GOOD MANUFACTURING PRACTICE; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; NUCLEIC ACID AMPLIFICATION; QUALITY CONTROL; REVIEW; RISK ASSESSMENT; SAFETY; SEVERE ACUTE RESPIRATORY SYNDROME; STEM CELL TRANSPLANTATION; WEST NILE FLAVIVIRUS;

CELL TRANSPLANTATION; COMMUNICABLE DISEASES; HUMANS; SAFETY; TISSUE TRANSPLANTATION;

EID: 33747119798     PISSN: 14451433     EISSN: 14452197     Source Type: Journal    
DOI: 10.1111/j.1445-2197.2006.03880.x     Document Type: Review

References (25)

1. Carrel A. Surgery of the blood-vessels and its application to the changes of circulation and transplantation of organs. John Hopkins Hosp. Bull. 1906; 184: 236-7.
2. Harrison RG, Greenman MJ, Mall FP, Jackson CM. Observations of the living developing nerve fiber. Anat. Rec. 1907; 1: 116-18.
3. Medawar PB. The behaviour and fate of skin autografts and skin homografts in rabbits. J. Anat. 1944; 78: 176-80.
4. Stramer SL, Glynn SA, Kleinman SH et al. Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. N. Engl. J. Med. 2004; 351: 760-68.
5. Goodman JL. The safety and availability of blood and tissues - progress and challenges. N. Engl. J. Med. 2004; 351: 819-22.
6. Galbraith DN. Regulatory and microbiological safety issues surrounding cell and tissue engineering products. Biotechnol. Appl. Biochem. 2004; 40: 35-9.
7. Kumar D, Prasad GV, Zaltzman J, Levy GA, Huma A. Community-acquired West Nile virus infection in solid-organ transplant recipients. Transplantation 2004; 77: 399-402.
8. Chakraborty C, Nandi S, Jana S. Prion disease: a deadly disease for protein misfolding. Curr. Pharm. Biotechnol. 2005; 2: 167-77.
9. Ironside JW, Head MW. Variant Creutzfeldt-Jakob disease: risk of transmission by blood products. Haemophilia 2004; 10 (Suppl. 4): 64-9.
10. Guide to the Preparation, Use and Quality Assurance of Blood Components, 10th edn. Strasbourg Cedex: Council of Europe Publishing, 2004.
11. GMP code of Human Blood and Tissue, Woden, Australia: Therapeutic Goods Administration, 2000.
12. Methods of preparation of sterile products. European pharmacopoeia 2004; 50: 443-9.
13. Zheng MH, Power RA, Openshaw JN et al. Effect of gamma irradiation on the mechanical properties of human cortical allograft bone. In: Kennedy JF, Phillips GO, Williams PA (eds). Sterilisation of Tissue Using Ionizing Radiations. CRC Press, 2005; 134-41.
14. Mitchell EJ, Stawatz AM, Kayacan R, Rimnac CM. The effect of gamma radiation sterilization on the fatigue crack propagation resistance of human cortical bone. J. Bone Joint Surg. Am. 2004; 86: 2648-57.
15. Blood and Blood Component, 9th edn. Strasbourg Cedex: Council of Europe Publishing, 2003.
16. Partsalis T, Chan LYS, Hurworth M et al. Evidence of circulating donor genetic material in bone allotransplantation. Int. J. Mol. Med. 2006; 17: 1151-5.
17. Braunfeld MY. Cadaveric donors. Anesthesiol. Clin. North America 2004; 22: 615-31.
18. Koostra G, Daeman JH, Oomen AP. Categories of non-heart beating donors. Transplant. Proc. 1995; 27: 2893-4.
19. Kainer MA, Linden JV, Whaley DN et al. Clostridium infections associated with musculoskeletal tissue allografts. N. Engl. J. Med. 2004; 350: 2564-71.
20. Brockbank DGM, Taylor MJ, Owen DR. Need for a systematic approach to organ recovery and technology development for the non-heart beating donor. Transplant. Proc. 2000; 32: 97-9.
21. Preti RA. Challenges associated with the development, manufacturing and delivery of cellular medicines. Cancer J. 2001; 7(Suppl. 2): 62-6.
22. Omstead DR, Baird LG, Christenson L et al. Voluntary guidance for the development of tissue engineered products. Tissue Eng. 1998; 4: 239-65.
23. Vaccines for human use. European Pharmacopoeia. 2004; 2649-51, No. 4.2.
24. Mayeno AN, Benson LM, Naylor S, Colberg-Beers M, Puchalski JT, Gleich GJ. Biotransformation of 3-(phenylamino)-1, 2-propanediol to 3-(phenylamino) alanine: a chemical link between Toxic Oil Syndrome and Eosinophilia-Myalgia Syndrome. Chem. Res. Toxicol. 1995; 8: 911-16.
25. Moos M Jr. Regulatory philosophy for comparability protocols. Dev. Biol. (Basel) 2002; 109: 53-6.